Showing results (1-10 of 437) with videos related to
Sort By:
Pageof 44
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 13, 2023
Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumoursYoichi Naito, Toshirou Nishida, Toshihiko DoiGan to Kagaku Ryoho. Cancer & Chemotherapy|July 20, 2016
[The Recommended Chemotherapy Duration-From the Viewpoint of Drug Resistance]Toshirou Nishida, Takahiro Kinoshita, Toshihiko DoiExpert Opinion on Pharmacotherapy|July 4, 2014
Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumorsToshirou Nishida, Toshihiko Doi, Yoichi NaitoInternational Journal of Clinical Oncology|April 25, 2009
Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT geneToshirou Nishida, Tsuyoshi Takahashi, Akiko Nishitani, et al.Investigational New Drugs|September 5, 2009
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylateKuniaki Shirao, Toshirou Nishida, Toshihiko Doi, et al.International Journal of Clinical Oncology|February 7, 2015
Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trialYoshito Komatsu, Toshihiko Doi, Akira Sawaki, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 22, 2018
[The Roles of Designated Core Hospitals and Cooperative Hospitals for Cancer Genomic Medicine in Japan]Toshirou NishidaTranslational Gastroenterology and Hepatology|March 20, 2018
Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelinesToshirou NishidaEuropean Journal of Cancer (Oxford, England : 1990)|September 20, 2019
Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trialToshihiko Doi, Yukinori Kurokawa, Akira Sawaki, et al.Pageof 44